(Q42770223)

7 November 2017

0 references

Preventing respiratory syncitial virus bronchiolitis (English)

1 reference

7 November 2017

0 references

M Sharland

1

1 reference

7 November 2017

A Bedford-Russell

series ordinal

2

1 reference

7 November 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

7 November 2017

1 reference

7 November 2017

322

1 reference

7 November 2017

7278

1 reference

7 November 2017

62-63

1 reference

RSV: Management of the acute episode

7 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1119371

Prevention of respiratory syncytial virus infection with palivizumab

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1119371

Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1119371

Immunoglobulin for preventing respiratory syncytial virus infection.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1119371

Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1119371

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1119371

Ribavirin and bronchiolitis: variation in use in the UK.

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1119371

Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1119371

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

16 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11154604

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11154604

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11154604

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1136/BMJ.322.7278.62

1 reference

7 November 2017

1 reference

7 November 2017

PubMed publication ID

11154604

1 reference